Liu J, Qin J, Liang L, Zhang X, Gao J, Hao Y, Zhao P (2024)
Publication Type: Journal article, Review article
Publication year: 2024
Book Volume: 979
Article Number: 176831
DOI: 10.1016/j.ejphar.2024.176831
Programmed cell death ligand 1 (PD-L1) interacts with programmed cell death 1 (PD-1), leading to T cell exhaustion and promoting tumor cell survival, ultimately mediating immunosuppression. While FDA-approved monoclonal antibodies targeting the PD-1/PD-L1 interaction have shown success in cancer treatment, some patients experience limited and short-lived therapeutic outcomes. Recent studies have identified PD-L1 expression not only on tumor cell surfaces but also on exosomes, with secretion pathways including both conventional and unconventional endocytosis routes, presenting a unique therapeutic opportunity. Emerging evidence suggests that exosomal PD-L1 contributes to systemic immunosuppression, potentially counteracting the effects of anti-PD-1 checkpoint therapies. However, the significance of exosomal PD-L1 in clinical cancer patients unresponsive to anti-PD-1/PD-L1 immunotherapy, as well as the factors regulating its generation, remain unclear. Moreover, the mechanisms underlying PD-L1 expression on exosomes and its regulation in cancer are yet to be fully elucidated. This review primarily focuses on the mechanisms modulating exosomal PD-L1 generation in cancer, while also outlining its involvement in immunosuppression, tumor proliferation, and response to cancer immunotherapy. Additionally, we explore the potential of exosomal PD-L1 as a cancer biomarker and therapeutic target, aiming to provide a comprehensive overview of this emerging field and its implications for cancer treatment and diagnosis.
APA:
Liu, J., Qin, J., Liang, L., Zhang, X., Gao, J., Hao, Y., & Zhao, P. (2024). Novel insights into the regulation of exosomal PD-L1 in cancer: From generation to clinical application. European Journal of Pharmacology, 979. https://doi.org/10.1016/j.ejphar.2024.176831
MLA:
Liu, Jie, et al. "Novel insights into the regulation of exosomal PD-L1 in cancer: From generation to clinical application." European Journal of Pharmacology 979 (2024).
BibTeX: Download